Latest News - Cencora
Top Corporates Hub
Cencora
Prescription for Beats: 3 Healthcare Stocks Set to Outperform in Q3
31.10.2025 14:15
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
Countdown to Cencora (COR) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
31.10.2025 13:15
Evaluate the expected performance of Cencora (COR) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Stocks making big moves this week: Cencora, Custom Truck One Source, Kirby, Mister Car Wash, and Cardinal Health
31.10.2025 13:00
Check out the companies making headlines this week:
United State Cell and Gene Therapy Third-Party Logistics Market Analysis Report 2025-2033: Expansion Fueled by Rising R&D Expenditure, Regulatory Complexity, & Strong Demand from Major Biopharma Hubs
28.10.2025 12:05
The U.S. Cell and Gene Therapy Third-Party Logistics (3PL) Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from 2025 to 2033. Key growth drivers include increased therapy adoption, specialized logistics needs, and expanding biopharmaceutical collaborations. Regulatory demands, cold chain technology adoption, and challenges such as logistics costs and workforce expertise underscore the market's evolution. States like California
World-Renowned Surgeon and Entrepreneur Dr. Mandeep S. Dhalla Invests in DentScribe.ai and Joins as Strategic Advisor
27.10.2025 06:12
DentScribe.ai, the agentic AI platform that transforms dental SOAP notes into real-time clinical checklists and practice growth signals, today announced that Dr. Mandeep S. Dhalla, MD, has invested in the company and joined as a Strategic Advisor.
Does Cencora’s Strong 42% Rally Signal More Growth Ahead in 2025?
13.10.2025 18:08
If you’re standing at a crossroads, wondering what to do with Cencora stock, you’re not alone. With shares closing recently at $318.00 and quietly notching up a 42.6% gain over the past year, there’s a real sense of momentum. The stock outperformed in the last five years too, leaping an astonishing 244.5%. That’s a growth story that’s caught more than a few eyes. Even over the most recent periods, Cencora’s consistency stands out, with a 4.2% uptick in just the last week and 5.1% over the...
Here's Why Cencora (COR) is a Strong Growth Stock
13.10.2025 13:45
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
10.10.2025 13:40
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
1 Surging Stock with Exciting Potential and 2 We Find Risky
26.09.2025 04:37
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Why Cencora (COR) Stock Is Trading Up Today
23.09.2025 19:30
Shares of healthcare distributor Cencora (NYSE:COR) jumped 4.5% in the afternoon session after peer company McKesson raised its long-term earnings growth outlook, boosting investor sentiment across the pharmaceutical distribution sector.
Here's Why You Should Hold Cencora Stock in Your Portfolio Now
05.09.2025 13:06
COR gains from strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose risks.
Cencora, Inc. (COR) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
05.09.2025 11:11
Explore Cencoraâs growth strategies, specialty market focus, and financial performance
The 5 Most Interesting Analyst Questions From Cencora’s Q2 Earnings Call
13.08.2025 05:34
Cencora’s third quarter results outperformed Wall Street’s expectations on both revenue and adjusted profit, but the market reacted negatively, reflecting investor concerns about slower growth in key areas. Management attributed the quarter’s outcomes to continued strength in U.S. Healthcare Solutions, particularly specialty distribution and higher utilization of pharmaceuticals, including GLP-1 products. However, CEO Robert Mauch and CFO James Cleary acknowledged moderating growth in GLP-1s and
COR Q2 Deep Dive: Specialty Growth, International Headwinds, and Guidance Update
12.08.2025 07:16
Healthcare distributor Cencora (NYSE:COR) announced better-than-expected revenue in Q2 CY2025, with sales up 8.7% year on year to $80.66 billion. Its non-GAAP profit of $4 per share was 4.2% above analysts’ consensus estimates.
Cencora (COR) Reports Q3 Earnings Growth, Maintains US$0.55 Dividend
07.08.2025 00:53
Cencora (COR) recently announced strong third-quarter earnings with sales at $80,664 million and net income rising to $687 million, reflecting significant growth. Despite these robust results, the stock price remained flat over the last quarter. These financial achievements, along with a quarterly dividend declaration of $0.55 per share, indicate Cencora's continued shareholder commitment. Although the broader market fluctuated amidst tariff news and earnings reports from other major firms,...
Cencora’s (NYSE:COR) Q2 Sales Top Estimates
06.08.2025 10:48
Healthcare distributor Cencora (NYSE:COR) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 8.7% year on year to $80.66 billion. Its non-GAAP profit of $4 per share was 4.2% above analysts’ consensus estimates.
Cencora: Fiscal Q3 Earnings Snapshot
06.08.2025 10:44
CONSHOHOCKEN, Pa. AP) — Cencora, Inc. COR) on Wednesday reported fiscal third-quarter earnings of $687.4 million.
Cencora Reports Fiscal 2025 Third Quarter Results
06.08.2025 10:30
CONSHOHOCKEN, Pa., August 06, 2025--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.52 for the third quarter of fiscal 2025 compared to $2.42 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, incr